| Literature DB >> 34168643 |
Long Li1, Kang Wei1, Yifan Ding1, Paerxiati Ahati1, Haoran Xu1, Huang Fang1, Huan Wang1.
Abstract
The accumulation of macrophages in degeneEntities:
Keywords: CHI3L1; M2a macrophage; MAPK; intervertebral disc degeneration; nucleus pulposus cell
Year: 2021 PMID: 34168643 PMCID: PMC8217759 DOI: 10.3389/fimmu.2021.666361
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Primers used in this study.
| Gene | Species | Forward | Reverse |
|---|---|---|---|
| CD206 | Human | aacggactgggttgctatca | cccgatcccttgtagagcat |
| CD301 | Human | gctgctggtcatcatctgtg | cctccacctcagctttcaga |
| Arginase1 | Human | gtggaagaaggccctacagt | gcttttcccacagaccttgg |
| GAPDH | Human | ccaaggagtaagacccctgg | tggttgagcacagggtactt |
| MMP3 | Rat | atgacagggaagctggactc | ctggagaatgtgagtggggt |
| MMP9 | Rat | aggatggtctactggcacac | gtgcaggacaaataggagcg |
| COL2A1 | Rat | tgttgacattgcacccatgg | cagccattcagtgcagatcc |
| Aggrecan | Rat | catgcatcctgtgaccactg | gcatcacttcacagcggtag |
| GAPDH | Rat | agacagccgcatcttcttgt | cttgccgtgggtagagtcat |
Figure 1Expression of the M2a macrophage marker, CD206, in human and rat degenerated intervertebral disc tissues. (A) Immunolocalization of CD206-positive cells in human intervertebral disc tissues. CD206-positive cells were detected using immunofluorescence staining with an anti-CD206 antibody. Representative pictures are from a patient with congenital scoliosis (11-year-old girl) and a patient with IDD (56-year-old woman), representing normal and IDD samples, respectively. (B) The ratio of CD206-positive samples between normal and IDD samples. CD206-positive cells were absent from normal disc samples (0/8, 0%), although seven of the 10 IDD samples exhibited at least one CD206-positive cell (7/10, 70%); Fisher’s exact test, **p < 0.01. (C) Immunolocalization of CD206-positive cells in rat intervertebral disc tissues. Intervertebral disc degeneration in a rat model was induced by needle puncture, and immunohistochemical staining of intervertebral disc tissues was performed with an anti-CD206 antibody. (D) Quantitative analysis of CD206 expression, the dates were analyzed by Student’s t -test. Significant differences between groups are shown as **p < 0.01.
Figure 2M2a macrophages promoted ECM degradation in NP cells. (A) Immunofluorescence analysis of the CD206 differentiation marker in M2a macrophages. M0 and M2a macrophages were differentiated from THP-1 monocytes by stimulation with phorbol 12-myristate 13-acetate or IL-4, respectively. Immunofluorescence staining for CD206 was performed. Scalebar, 100 µm. (B) Semi-quantitative analysis of CD206 immunofluorescence staining results. (C) Western blotting analysis of CD206 differentiation marker in M2a macrophages. M0 and M2a macrophages were differentiated from THP-1 monocytes. The protein levels of CD206 in THP-1, M0 (i.e., control), and M2a macrophages were determined by western blotting. (D) Quantification of CD206 protein levels in western blots. (E) qRT-PCR analysis of M2a macrophage differentiation marker genes (CD204, CD206, and arginase-1). (F) Effects of M2a macrophages on NP cells via Transwell co-culture. M0 and M2a macrophages were differentiated from THP-1 monocytes, then co-cultured with NP cells for 48 h. MMP3, MMP9, collagen II, and aggrecan expression levels of NP cells were analyzed by qRT-PCR. Experiments were repeated three times in triplicate. The dates were analyzed by One-way analysis of variance (ANOVA). Statistically significant difference: **P < 0.01.
Figure 3CHI3L1 mediated M2a macrophage-induced ECM degradation. (A) Expression of CHI3L1 in M2a macrophages. M0 and M2a macrophages were differentiated from THP-1 monocytes. The protein levels of CHI3L1 in THP-1, M0 and M2a macrophages were detected by western blotting. (B) Quantification of CHI3L1 protein levels in western blots. (C) siRNA silencing of CHI3L1 in M2a macrophages. After transfection with NC siRNA or CHI3L1 siRNA, the knockdown of CHI3L1 in M2a macrophages was confirmed by western blotting. (D) Quantification of CHI3L1 protein levels in western blots. (E) Effects of CHI3L1 silencing in M2a macrophages on ECM degradation in NP cells. After co-culture with CHI3L1-silenced M2a macrophages, the expression levels of MMP3, MMP9, collagen II and aggrecan in NP cells were analyzed by qRT-PCR. Experiments were repeated three times in triplicate. The dates were analyzed by One-way analysis of variance (ANOVA). Significant differences between groups are shown as **p < 0.01. #, no statistical difference.
Figure 4rCHI3L1 promoted ECM metabolism in NP cells. (A) Effects of rCHI3L1 concentration gradient on ECM metabolism in NP cells. Following incubation with different doses of rCHI3L1 for 48 h, the protein levels of MMP3, MMP9, collagen II and aggrecan in NP cells were detected by western blotting. (B) Quantification of the protein levels in (A, C) Effects of rCHI3L1 on ECM metabolism at different time points. NP cells were treated with rCHI3L1 (150 ng/ml) for 24 or 48 h. The protein levels of MMP3, MMP9, collagen II and aggrecan were detected by western blotting. (D) Quantification of the protein levels in (C) Data are presented as means ± standard deviations (n = 3) from one representative experiment of three independent experiments performed in triplicate. The dates were analyzed by One-way analysis of variance (ANOVA). Significant differences between groups are shown as **p < 0.01.
Figure 5IL-13Rα2 was involved in CHI3L1-induced ECM metabolism. (A) Co-localization of CHI3L1 and IL-13Rα2 proteins in NP cells. After treatment with rCHI3L1 (150 ng/ml) for 24 h double immunofluorescence staining was performed on NP cells with anti-CHI3L1 and anti-IL-13Rα2 antibodies. (B) IL-13Rα2 was silenced in NP cells by siRNA. NP cells were transfected with NC siRNA or IL-13Rα2 siRNA, then grown for 24 h. Knockdown of IL-13Rα2 was confirmed by western blotting. (C) Quantification of the protein levels of IL-13Rα2 in western blots. (D) Effects of IL-13Rα2 silencing on CHI3L1-induced ECM metabolism. After transfecting with NC siRNA or IL-13Rα2 siRNA for 24 h, NP cells were incubated with rCHI3L1 (150 ng/ml) for another 24 h. The protein levels of MMP3, MMP9, collagen II, and aggrecan were detected by western blotting. (E) Quantification of the protein levels in (D). Data are presented as means ± standard deviations (n = 3) from one representative experiment of three independent experiments performed in triplicate. The dates were analyzed by One-way analysis of variance (ANOVA). Significant differences between groups are shown as **p < 0.01.
Figure 6CHI3L1 promoted ECM degradation through the MAPK pathway in NP cells. (A) CHI3L1 affected the MAPK pathway at different time points. NP cells were incubated with rCHI3L1 (150 ng/ml) at different time points (10, 30, and 60 min). The MAPK activation was detected by western blotting. (B) Quantification of the protein levels in (A, C) IL-13Rα2 was involved in the CHI3L1-induced activation of the MAPK pathway. The IL-13Rα2-silenced NP cells were incubated with rCHI3L1 (150 ng/ml) for 60 min. The MAPK pathway related proteins were detected by western blotting. (D) Quantification of the protein levels in (C). (E) The MAPK signaling pathway was involved in CHI3L1-induced ECM degradation. After treatment with U0126 (ERK inhibitor) or SP600125 (JNK inhibitor) at 10 µM for 6 h, NP cells were incubated with rCHI3L1 (150 ng/ml) for 24 h. MMP3, MMP9, collagen II, and aggrecan expression levels were analyzed by qRT-PCR. Data are presented as means ± standard deviations (n = 3) from one representative experiment of three independent experiments performed in triplicate. The dates were analyzed by One-way analysis of variance (ANOVA). Significant differences between groups are shown as **p < 0.01. #, no statistical difference.
Figure 7Diagram of the possible mechanism that M2a macrophage promotes intervertebral disc degeneration (IDD). M2a macrophage-secreted CHI3L1 promoted the expression of catabolism genes (MMP-3 and MMP-9) and suppressed the expression of anabolism genes (aggrecan and collagen II) in NP cells via activation of IL-13Rα2/MAPK pathway.